1. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

    Alzheimer's & Dementia 11(7):772 (2015) PMID 26194312

    We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and i...
  2. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.

    Alzheimer's & Dementia 11(7):734 (2015) PMID 26194309

    This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors...
  3. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

    Alzheimer's & Dementia 11(7):865 (2015) PMID 26194320

    The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. We searched for ADNI publications using established methods. ADNI has (1) developed s...
  4. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

    Alzheimer's & Dementia 11(6):e1 (2015) PMID 26073027

    The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The initial study, ADNI-1, enrolled 400 subjects with...
  5. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

    Annals of clinical and translational neurology 2(5):534 (2015) PMID 26000325 PMCID PMC4435707

    To find the combination of candidate biomarkers and cognitive endpoints to maximize statistical power and minimize cost of clinical trials of healthy elders at risk for cognitive decline due to Alzheimer's disease. Four-hundred and twelve cognitively normal participants were followed over 7 year...
  6. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.

    JAMA Neurology 72(4):446 (2015) PMID 25706191 PMCID PMC4397164

    Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individuals at the preclinical stage. The success of these trials depends on validated outcome measures that are sensitive to early clinical progression in individuals who are initially asymptomatic. To i...
  7. Brain structure and function as mediators of the effects of amyloid on memory.

    Neurology 84(11):1136 (2015) PMID 25681451 PMCID PMC4371407

    The objective of this study was to test whether effects of β-amyloid (Aβ) pathology on episodic memory were mediated by metabolism and gray matter volume in the early stages of Alzheimer disease. This was a prospective cohort study. We measured baseline Aβ (using florbetapir-PET), brain function...
  8. Protective variant for hippocampal atrophy identified by whole exome sequencing.

    Annals of Neurology 77(3):547 (2015) PMID 25559091

    We used whole-exome sequencing to identify variants other than APOE associated with the rate of hippocampal atrophy in amnestic mild cognitive impairment. An in-silico predicted missense variant in REST (rs3796529) was found exclusively in subjects with slow hippocampal volume loss and validated...
  9. Protective variant for hippocampal atrophy identified by whole exome sequencing.

    Annals of Neurology 77(3):547 (2015) PMID 25559091 PMCID PMC4387567

    We used whole-exome sequencing to identify variants other than APOE associated with the rate of hippocampal atrophy in amnestic mild cognitive impairment. An in-silico predicted missense variant in REST (rs3796529) was found exclusively in subjects with slow hippocampal volume loss and validated...
  10. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.

    Neurobiology of Aging 36(1):273 (2015) PMID 25175807

    The goal of this study was to identify factors contributing to hippocampal atrophy rate (HAR) in clinically normal older adults (NC) and participants with mild cognitive impairment (MCI). Longitudinal HAR was measured on T1-weighted magnetic resonance imaging, and the contribution of age, gender...
  11. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

    Expert Review of Neurotherapeutics 15(1):83 (2015) PMID 25537424

    Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Co...
  12. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.

    Neurobiology of Aging 36(1):273 (2015) PMID 25175807

    The goal of this study was to identify factors contributing to hippocampal atrophy rate (HAR) in clinically normal older adults (NC) and participants with mild cognitive impairment (MCI). Longitudinal HAR was measured on T1-weighted magnetic resonance imaging, and the contribution of age, gender...
  13. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

    Expert Review of Neurotherapeutics 15(1):83 (2015) PMID 25537424

    Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Co...
  14. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

    Expert Review of Neurotherapeutics 15(1):83 (2015) PMID 25537424

    Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Co...
  15. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.

    Neurobiology of Aging 36(1):273 (2015) PMID 25175807

    The goal of this study was to identify factors contributing to hippocampal atrophy rate (HAR) in clinically normal older adults (NC) and participants with mild cognitive impairment (MCI). Longitudinal HAR was measured on T1-weighted magnetic resonance imaging, and the contribution of age, gender...
  16. Advances in Alzheimer's disease drug development.

    BMC Medicine 13(1):62 (2015) PMID 25857341 PMCID PMC4373002

    Alzheimer's disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional dependency. Recent biomarker studies indicate that AD is characterized by a lo...
  17. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

    Alzheimer's Research & Therapy 7(1):36 (2015) PMID 26064192 PMCID PMC4461930

    The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic effects a...
  18. Estimating long-term multivariate progression from short-term data.

    Alzheimer's & Dementia 10(5 Suppl):S400 (2014) PMID 24656849 PMCID PMC4169767

    Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich pa...
  19. Estimating long-term multivariate progression from short-term data

    Alzheimer's & Dementia 10(5):S400 (2014)

    Motivation Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaire...
  20. Estimating long-term multivariate progression from short-term data.

    Alzheimer's & Dementia 10(5 Suppl):S400 (2014) PMID 24656849 PMCID PMC4169767

    Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich pa...